SOURCE: BioProgress PLC

January 25, 2007 02:01 ET

BioProgress plc announces Conference Presentation

Cambridgeshire -- (MARKET WIRE) -- January 25, 2007 --

For Immediate Release                                     25 January 2007

                                BioProgress plc

                                Arab Health 2007
London, UK, 25 January 2007: BioProgress plc ('BioProgress' or the 'Company') (AIM: BPRG; NASDAQ: BPRG), the speciality pharma and healthcare announces that it will be showing its technologies and products at Arab Health, Dubai on 29 January - 01 February.

Arab Health is attended by over 33,000 visitors with 2,200 exhibiting companies. With many of the global and regional pharmaceutical companies attending, Arab Health 2007 offers BioProgress a central forum targeting a global audience. We plan to extend our strategic relationships, and target additional distributors for our current portfolio of over 40 pharmaceutical and healthcare products, and five commercialised enabling systems.

For more details on Arab Health 2007, visit

Steve Martin, Chief Development Officer said:

"Arab Health is an important forum to show our products and technologies to a wide global audience. This is the first time we have shown at Arab Health and represents a significant step forward for the company where we are showcasing over 40 products, and a range of unique enabling drug delivery systems."

For further information:

BioProgress Plc                               + 44 (0) 20 7098 9881
Richard Trevillion, CEO

Steve Martin, CDO

Buchanan Communications                       + 44 (0) 20 7466 5000
Rebecca Skye Dietrich / Mark Court

About BioProgress

BioProgress plc is an innovative specialty pharmaceutical and healthcare business based around its platform technologies in polymer and film systems. Listed on London's AIM in May 2003 and on US NASDAQ in October 2004, the company has over 80 patents granted or in application within 24 patent families and has product development agreements and strategic alliances with several global companies. As a virtually integrated business, BioProgress has acquired sales and marketing resources within Europe and the US as a launch mechanism for its own pharmaceutical products. The business continues to develop innovative delivery mechanisms using its XGEL™polymer technology, replacing the need to use animal-derived gelatine in pharmaceutical and healthcare products. For further information please go to

Forward-Looking Information.

The Ordinary Shares of BioProgress plc are registered under the US Securities and Exchange Act of 1934. To the extent that this announcement contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, this paragraph applies. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may vary materially from the expectations contained in the forward-looking statements. The forward-looking statements in this release include statements addressing future financial and operating results and the timing and benefits of the reorganisation. Detailed information about factors pertinent to the business of the company that could cause actual results to differ is set forth in the Company"s filings with the Securities and Exchange Commission. The Company is under no obligation to (and expressly disclaim any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise. This announcement is for information only and does not constitute an offer or invitation to acquire or dispose of any securities or investment advice. The distribution of the announcement and/or issue of securities in certain jurisdictions may be restricted by law. Persons into whose possession this announcement comes are required to inform themselves about and to observe such restrictions.

                      This information is provided by RNS
            The company news service from the London Stock Exchange